Drug Profile
TSB 9 W1
Alternative Names: IDS; TSB-9-W1Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Taiwan Sunpan Biotechnology Development
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Neoplasm protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (PO, Capsule)
- 25 Aug 2020 Taiwan Sunpan Biotechnology Development completes a phase i trial in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Taiwan (PO) (NCT02249650)